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Abstract
Breast cancer is a major health concern as it is the second leading cause of death 
from cancer. There are several well-known risk factors that contribute to breast can-
cer. Despite the various treatment options available, complete cure is still difficult 
due to heterogenicity of BC subtypes. As a result, identifying BC subtypes is critical 
for determining the optimal treatment approach. Over the last several years, new 
drugs targeting particular therapeutic targets have resulted in significant advances 
in the treatment of breast cancer. Nonetheless, resistance to treatment is the “major” 
issue, and a significant increase in survival rates has been the main focus for 
researchers. The purpose of this review article is to provide a broad overview of the 
molecular basis of drug resistance in breast cancer, as well as a detailed assessment 
of current treatment options, potential new treatment methods for drug-resistant 
breast cancer and repurposed drugs used for treatment. The possibility of non-can-
cer drugs being studied for breast cancer in the future, as well as the obstacles and 
bottlenecks of drug repurposing, is also highlighted. Finally, we go through present 
problems and future prospects in drug-resistant breast cancer therapy.
Keywords: Breast Cancer, Endocrine Resistance, Oestrogen Receptor Modulation, 
Drug Repurposing
1. Introduction
Breast cancer is the most frequent disease among women, according to the 
World Health Organisation (WHO), and it is the second leading cause of death 
from cancer, after lung cancer. It is considered a severe health concern that affects 
patients’ quality of life as well as their psychological well-being, It is the main cause 
of death among women aged 45 to 55 years old. The incidence of breast cancer is 
expected to grow by 85 per 100.000 women by 2021 [1]. Experts estimate that by 
2050, there will be approximately 3.2 million new BC cases each year worldwide, 
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based on population increase. Although there is no single risk factor for the majority 
of breast cancer patients, there are a number of well-known risk factors, including 
obesity, lack of physical activity, consumption of alcohol, hormone replacement 
therapy, increased breast density, and inherited genetic susceptibility due to muta-
tions in autosomal dominant genes, which contribute for 5–10% of all breast cancer 
cases in the United States [2]. Treatment for BC is difficult since it is a heteroge-
neous illness with various subtypes that have different but distinct clinical and 
biochemical characteristics. As a result, identifying BC subtypes is critical for deter-
mining the optimal treatment approach [3]. Breast cancer may be in situ or invasive, 
with in situ tumours being the easiest to cure. Invasive breast cancers, especially 
invasive ductal carcinoma (which accounts for 80% of all invasive breast cancers), 
are a major source of concern. While receptor-specific therapy is used to treat the 
first two types of breast cancer, chemotherapy remains the mainstay of TNBC 
treatment [4]. BC is characterised as basal-like or non-basal-like according on the 
cell type of origin (luminal or basal/myoepithelial cell compartment). The afore-
mentioned, also referred to as “triple-negative,” contributes approximately 10% of 
all BCs. Understanding the etiological heterogeneity of BC subgroups will aid in 
directing therapy, predicting survival, and impacting preventive measures due to 
the complexity of biology [5]. With the standardisation of systemic chemotherapy 
as the gold-standard method for most cancer types and the moderate increase 
in both survival rates and toxicity reduction, targeted therapy has undoubtedly 
garnered the greatest scholarly attention and financing from the pharmaceutical 
sector. Nonetheless, resistance to treatment is the “major” issue, and a significant 
increase in survival rates is still a pipe dream for researchers. It is important to note 
that tremendous progress has been achieved in the area of breast cancer research 
during the last decade. The ‘battle’ against this mysterious and aggressive form of 
cancer, however, is still ongoing [6]. The purpose of this review article is to provide 
a broad overview of the molecular basis of drug resistance in breast cancer, as well 
as a detailed assessment of current treatment options and potential new treatment 
methods for drug-resistant breast cancer. Finally, we go through present problems 
and future prospects in drug-resistant breast cancer therapy.
2. Breast cancer risk factors
BC is associated with the following epidemiological risk factors: (a) a younger 
age at the first menstrual cycle and during the first birth, (b) pre-menopause is 
the prime factor in most BC patients, (c) civilization is an unavoidable outcome 
of increased risk for BC fatalities, (d) socio - economic background is an unbiased 
predictor of sophisticated extent at assessment in breast cancers, and (e) obesity 
and higher BMI are epidemiological risk factors for BC (Figure 1).
3. Pathogenesis
Breast cancers typically begin as ductal hyperproliferation and progress to 
benign tumours or even metastatic carcinomas as a result of continuous stimulation 
by carcinogenic agents. Breast cancer initiation and progression are influenced by 
tumour microenvironments such as stromal effects and macrophages. When only 
the stroma, not the extracellular matrix or the epithelium, was exposed to carcino-
gens, the mammary gland of rats may be driven to neoplasms. Macrophages may 
create a mutagenic inflammatory microenvironment, allowing cancer cells to avoid 
immune rejection and increase angiogenesis. The normal and tumour-associated 
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microenvironments exhibit different DNA methylation patterns, suggesting that 
epigenetic changes in the tumour tissue may promote tumorigenesis. Cancer stem 
cells (CSCs), a new type of malignant cell seen in tumours, have been linked to 
tumour genesis, migration, and relapse. This minor group of cells can auto renew 
and is resistant to chemotherapy and radiation. They may be produced from stem 
Figure 1. 
The risk factors of breast cancer.
Figure 2. 
The possible hypothesis for onset and development of breast cancer.
Drug Repurposing - Molecular Aspects and Therapeutic Applications
4
cells or progenitor cells in normal tissues. Ai Hajj was the first to identify breast 
cancer stem cells (bCSCs), demonstrating that as few as 100 bCSCs can create new 
tumours in infected mice. Luminal epithelial progenitors are more likely than basal 
stem cells to give rise to bCSCs. Wnt, Notch, Hedgehog, p53, PI3K, and HIF are all 
signalling pathways involved in the auto-renewal, multiplication, and migration of 
bCSCs. However, more research is needed to fully comprehend bCSCs and create 
ingenious ways for their eradication. The cancer stem cell theory and the stochastic 
theory are two distinct hypotheses for breast cancer initiation and progression. 
All tumour subtypes, according to the cancer stem cell theory, are derived from 
the same stem cells or transit-amplifying cells (progenitor cells). Various tumour 
features will result from acquired genetic and epigenetic alterations in stem cells 
or progenitor cells (Figure 2). According to the stochastic theory, each tumour 
subtype begins from a single type of cell (stem cell, progenitor cell, or differenti-
ated cell) (Figure 2). Any breast cell can acquire random mutations over time, 
eventually transforming it into a tumour cell if enough mutations are accumu-
lated. Despite the fact that both theories are backed up by evidence, neither can 
adequately explain the origins of human breast cancer [7].
4. Types of breast cancer
According to a review, breast cancer is divided into invasive and noninvasive 
breast cancers Figure 3.
4.1 Non-invasive breast cancer
It’s a malignancy that has not spread beyond the lobule or ducts in which it’s 
found [8]. Ductal carcinoma in situ is an example of a kind of non-invasive breast 
cancer. Ductal carcinoma in situ develops when abnormal cells form inside the milk 
ducts but do not spread to nearby tissue or to the outside. The term “in situ” means 
“in place.” Atypical cells may develop and mature into invasive breast cancer even if 
they have not spread beyond the lobules or ducts.
4.2 Lobular carcinoma in situ (LCIS)
Breast lobules form as a result of this kind of breast cancer. Outside of the 
lobules, the breast cancer has not spread into the breast tissue. Non-invasive breast 
cancer is typically diagnosed as lobular carcinoma in situ.
Figure 3. 
Types of breast cancer.
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4.3 Ductal carcinoma in situ
It is the most common type of non-invasive breast cancer, because it only affects 
the breast duct. Ductal comedocarcinoma is an example of ductal carcinoma in situ.
4.4 Invasive breast cancer
When abnormal cells from the lobules or milk ducts break off and come into 
contact with breast tissue, this condition occurs. Through the immune system or the 
systemic circulation, cancer cells may spread from the breast to other areas of the 
body. They may migrate early in the formation of the tumour, when it is small, or 
later, when it is large. Invasive breast cancer is the most common kind of cancer in 
women. Metastatic breast cancer is defined as invasive breast cancer that has spread 
to other parts of the body. The brain, bones, lungs, and liver are the most frequent 
organs to which these cells travel. These cells separate and grow irregularly once 
again, resulting in new tumours. Although new forming cells are appearing in many 
parts of the body,but still remains to be breast cancer cells [9, 10].
4.5 Infiltrating lobular carcinoma (ILC)
Invasive lobular carcinoma is another name for infiltrating lobular carcinoma. 
ILC begins in the breast milk glands (lobules), but it may spread to other parts of 
the body.
4.6 Infiltrating ductal carcinoma
Invasive ductal carcinoma is also known as infiltrating ductal carcinoma. IDC 
begins in the breast milk ducts and spreads to the duct wall, infecting the fatty 
tissues of the breast and perhaps other areas of the body.
4.7 Medullary carcinoma
Invasive breast cancer with a distinct normal and medullary tissue border is 
known as medullary carcinoma.
4.8 Mucinous carcinoma
Mutinous carcinoma, sometimes called colloid carcinoma, is an uncommon kind 
of breast cancer characterised by cancer cells that produce mucus. Females who 
have mutinous carcinoma have a better prognosis than those who have other kinds 
of invasive carcinoma.
4.9 Tubular carcinoma
Tubular invasive breast carcinomas are a form of invasive breast carcinoma. 
Tubular carcinoma had a better prognosis than other forms of invasive carcinoma.
4.10 Inflammatory breast cancer
Inflammatory breast cancer causes swollen (red and heated) breasts with 
bulges and/or broad ridges, which happens when cancer cells block lymph arter-
ies or channels in the skin surrounding the breast. Inflammatory breast cancer 
is an uncommon kind of cancer that rapidly spreads. Throughout treatment, all 
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multidisciplinary techniques, including as radiation therapy, surgery, chemo-
therapy, and imaging, must be carefully integrated. Since the first publication on 
this subject, neoadjuvant chemotherapy has resulted in a substantial increase in 
overall survival and has taken the place of locoregional treatments like radiation 
and surgery, resulting in long-term improvements in this disease [11, 12].
4.11 Paget’s disease of the breast
It’s an uncommon kind of breast cancer that produces visible changes to the 
breast’s nipple. Red itchy rashes around the nipple, which may occasionally spread 
to the rest of the body, are among the symptoms. Paget’s disease of the breast 
differs from other skin problems like eczema and psoriasis in that the other skin 
problems usually affect both breasts and can start at the areola rather than the 
nipple of the breast, whereas Paget’s disease of the breast usually affects only one 
breast and starts at the nipple of the breast rather than the areola. Men and women 
are equally affected by Paget’s disease, which contributes for 1–3% of all breast 
malignancies.
4.12 Phyllodes tumour
Tumours caused by Phyllodes may be benign or malignant. Phyllodes tumours 
grow in the breast’s connective tissues and may be surgically removed. Phylloides 
tumours are very rare; in the United States, less than 10 women die of this kind of 
breast cancer each year [13–15].
4.13 Triple-negative breast cancer
Breast cancer is now well understood to be a diverse disease with several sub-
forms characterised by their distinct clinico-pathological features, prognosis, and 
treatment responses. The absence of progesterone receptor, human epidermal 
growth factor receptor 2, and oestrogen receptor expression characterises triple-
negative breast cancer. This kind is primarily destructive, and it is more frequent 
in premenopausal females. It accounts for 10–15 percent of cases in white females, 
with a higher frequency.
5. Stages of breast cancer
5.1 Stage 0
This is a non-invasive tumour stage in which both cancerous and non-cancer-
ous cells are enclosed within the boundaries of the breast part where the tumour 
begins to grow, with no evidence of their invasion into the surrounding tissues 
of that part; ductal cell carcinoma in situ (DCIS) is an example of this tumour 
stage [16].
5.2 Stage 1
Invasive breast cancer is described as this stage, and microscopic invasion is 
conceivable. It is divided into two stages: 1A and 1B. Te category 1A refers to a 
tumour that is up to 2 cm in diameter and does not include any lymph nodes, while 
stage 1B refers to a tiny collection of cancer cells bigger than 0.2 mm discovered in a 
lymph node [17].
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5.3 Stage 2
Stage 2 is divided into two categories: 2A and 2B. The tumour is detected in axil-
lary lymph nodes or sentinel lymph nodes in Stage 2A, but there is no tumour in the 
breast. The tumour may be 2 cm in diameter or 5 cm in diameter. Stage 2B, on the 
other hand, defines a tumour that is bigger than 5 cm in diameter but does not reach 
the axillary lymph nodes [18].
5.4 Stage 3
It’s broken down into four sections: 3A, 3B, and 3C. Stage 3A refers to a tumour 
that has caused swelling or ulceration on the breast skin and has spread to up to 9 
axillary lymph nodes or sentinel lymph nodes, whereas stage 3B refers to a tumour 
of any size that has caused swelling or ulceration on the breast skin and has spread 
to up to 9 axillary lymph nodes or sentinel lymph nodes. Because it has progressed 
to 9 axillary lymph nodes or sentinel lymph nodes, stage 3B breast cancer is deemed 
inflammatory. Tumour spread to 10 or more axillary lymph nodes, as well as lymph 
nodes above and below the clavicle, is classified as stage 3C [19].
5.5 Stage 4
This is the late and metastatic stage of cancer, in which the disease has spread to 
other internal organs including the lungs, bones, liver, and brain Figure 4 [20].
6. Clinical breast cancer diagnosis techniques
The assessment methods and popular imaging techniques that will aid physicians in 
providing better care to patients and advancing clinical diagnosis are discussed below.
1. History and physical examination of breast cancer
The clinical history of breast cancer patients is used to assess the risk of developing 
cancer and to show the existence or absence of breast disease symptoms [21]. Age 
at menarche, menopausal status, prior pregnancies, and usage of hormone replace-
ment therapy or oral contraceptives beyond menopause are all factors to consider. 
Personal as well as family history should be carefully investigated. Breast soreness, 
weight loss, bone pain, tiredness, and nipple discharge are just a few of the symp-
toms to check into. During a physical examination, doctors look at the breasts, the 
area around the neck and collarbone, and the armpits (axillae). Any anomalies in 
the breasts, such as lumps or other breast cancer signs, are investigated. Lymph 
nodes, which are often enlarged in breast cancer patients, are also assessed [22, 23].
2. Self examination
The value of breast self-examination is debatable since no benefit in terms of 
decreased mortality has been demonstrated. Most doctors teach women to do 
monthly self-examinations in order to get familiar with their normal structure 
and to give them authority over their own healthcare. Self-examination may 
reveal irregularities in breast size and form. Sreedharan et al. performed re-
search at hospitals in the United Arab Emirates. A self-administered structured 
questionnaire was utilised to look at self-examination and knowledge prac-
tises. This research [24] produced satisfactory outcomes. These studies have 
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demonstrated that a continuous breast cancer education programme may help 
people become more aware of the disease. Ceber et al. performed research on 
Turkish women’s breast self-examination and health attitudes, concluding that 
early detection of breast cancer may avoid physical diseases and early mortal-
ity. He further claimed that just one out of every seven patients with breast 
cancer receives a timely diagnosis [25].
3. Mammography
Mammography (MG) is the recommended method for screening and detecting 
breast cancer, and it aids physicians in gathering clinic data on BC patients. The data 
indicates that early MG screening may decrease the death rate of BC patients by 30 
percent to 40 percent [26]. Meanwhile, only 4 percent −10 percent of BC patients 
have MG as a positive diagnostic finding. With the passage of time, MG continues 
to grow. The two primary methods for diagnosing BC patients in clinic are contrast-
enhanced mammography (CEM) and digital breast tomosynthesis (DBT) [27, 
28]. Age, ethnicity, personal history, radiologist expertise, and technique quality 
all influence mammography sensitivity. In high-density breasts in premenopausal 
women, sensitivity may be decreased. Mammography has a number of disadvan-
tages, including the use of ionising radiation, inability to diagnose thick breasts, 
high false-positive and false-negative rates, and an unpleasant examination.
4. Ultrasonography
Breast ultrasonography is a low-cost and commonly available screening 
method that detects malignancies by rebounding acoustic waves off breast 
tissue. To identify the anatomy of the human breast, an ultrasonic transducer 
is utilised to detect the acoustic waves reflected off it. Although less efficient 
Figure 4. 
Stages in development of breast cancer.
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than mammography, breast ultrasonography increases cancer detection rates 
in high-risk women and helps in the identification of cysts and solid masses. 
For women at high risk of breast cancer, pregnant women, and those who are 
unable to undergo mammography, breast ultrasonography has been recom-
mended as a supplement to mammography. When breast ultrasonography and 
mammography are used together, the sensitivity of the imaging increases at 
the cost of specificity and biopsy rates. Because the reverberant characteristics 
of healthy and malignant tissues are so similar, breast ultrasonography fails to 
identify many tumours. It also necessitates the employment of qualified radi-
ologists, which has a big impact on sensitivity and specificity [29].
5. Magnetic resonance imaging
MRI creates pictures at different cross-sections by mixing a strong magnetic 
field with RF signals. Breast MRI is suggested for high-risk women, but not for 
the general population because of its high rate of inaccuracy, higher expense, 
time commitment, insufficient number of units, requirement for trained ra-
diologists, and lack of therapeutic effect. The American Cancer Society (ACS) 
has published recommendations for utilising MRI as a complement to mam-
mography, and for specific demographic groups, such as BRCA mutation car-
riers and those at higher risk of complications, annual MRI scans are advised. 
In women at high risk of breast cancer, MRI is less specific but more sensitive 
than mammography and ultrasound in identifying small lesions [30].
6. Nuclear medicine
It is a kind of molecular imaging in which a person is administered a radioac-
tive substance, and the radiation released by the radiopharmaceutical is shown 
by sensitive emission detectors such as gamma cameras and PET detectors 
located outside the patient’s body. The combination of a CT scanner and a 
gamma camera, as well as a CT scanner and a PET scanner, is a significant 
advance in the identification and localization of disease.
7. Single photon emission computerised tomography (SPECT)
This method employs single photon radionuclides that produce gamma rays, 
such as gallium-67, iodine-131, and technicium-99. It’s a fast and precise scan 
for the organ of concern. It may be used over the whole body, is quite safe in 
terms of radiation dose, and is effective in detecting both primary and meta-
static tumours. The abbreviation PET/CT refers to positron emission tomogra-
phy. PET/CT is also low-radiation since it utilises positron-emitting radionu-
clides including oxygen-15, fluoride-18, and carbon-11 to produce positrons. In 
positron emission tomography, a radioactive version of glucose, such as [18F]
fuoro-2-deoxy-d-glucose, is a typical tracer. Tissues with greater metabolic 
needs, such as developing cancer cells, absorb the tracer more readily, which 
is seen on the scan. Using a combination of CT and PET, significant informa-
tion about a range of situations impacting the different organs of the body may 
be readily mapped. PET/CT is extremely sensitive and accurate for predicting 
opaque and distinct areas of loco-regional lymph nodal extent and/or far-away 
metastases that are not apparent on conventional imaging, with up to 25% of 
patients having their staging changed. This technique is used to plan manage-
ment by describing the primary disease’s spread. It’s also utilised in re-staging 
and treatment follow-up after a return of a managed disease [31].
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8. Tumour markers
Tumour markers should be examined at all stages of breast cancer therapy, 
diagnosis, and screening, including metastasis prediction, treatment, and 
diagnosis, according to Porika et al. Thirteen distinct breast cancer tumour in-
dications are investigated, six of which are new to the guideline. The different 
variations have been proven to be therapeutically useful and are recommended 
for use in clinical practice [32]. In order to avoid over- or under-interpreting 
the therapeutic potential of a few studies, the physician must be aware of the 
limits in the combined specificity and sensitivity of each sign. With these re-
strictions in mind, submitting tissue, germ-line, and soluble tumour markers 
for clinical trials may assist individuals who are at risk for or have breast cancer 
get back on track with their treatment.
9. Breast biopsy
Breast biopsies are the most effective way to find out whether you have breast 
cancer. Biopsies of the breast occur in a range of sizes and forms. To enhance 
diagnosis accuracy and remove as many false negative results as possible, 
breast imaging, breast self - examination, and biopsy are all performed at the 
same time (triple test).
a. Fine needle aspiration
A thin prickle is used to extract cells from an abnormal area or a breast nodule. 
Ultrasound may be used to guide the prickle. A local anaesthetic may be used 
to anaesthetize the region where the prickle will be inserted.
b. Core biopsy
A larger prickle is used to extract a core of tissue from the abnormal region or 
breast lump. It is usually performed under a limited anaesthesia, so the breast 
is unaffected, and the patient may feel no pain or discomfort depending on 
when the anaesthetic is administered. For the length of the core biopsy, an 
MRI, ultrasound, or mammography may be utilised to guide the procedure.
c. Vacuum-assisted stereotactic core biopsy
Different small tissue samples are obtained through a single tiny incision in 
the skin using a prickle and a suction-type device in this core biopsy. It is done 
with the use of a local anaesthetic. To guide the prickle into place, an MRI, 
ultrasound, or mammography may be used. During the procedure, the patient 
may feel a bit uneasy.
d. Surgical biopsy
A surgical biopsy is performed if the abnormal site is too small to be biopsied 
by another technique or if the biopsy result is unclear. A guide wire may be 
inserted into the breast prior to the biopsy to aid the medical practitioner in 
locating the abnormal tissue. A local anaesthetic may be administered, and the 
wire can be guided into place using MRI, ultrasound, or mammography. After 
that, a general anaesthesia is used to perform the biopsy. Along with the wire, 
a little region around the breast tissue and lump is removed.
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7. Treatment methods
The goal of breast cancer treatment is to maintain quality of life while extending 
life expectancy. Breast cancer treatment methods vary based on the stage of the 
disease, its size, location, whether it has spread to other organs of the body, and 
the individual’s physical state. Targeted treatments, hormone treatment, radiation 
therapy, and surgery are being used to treat breast cancer.
1. Surgery
This is the most common treatment option for people with breast cancer that 
has not spread to other parts of the body, and it’s also a viable option for those 
with more advanced stages of the disease. The amount of tissue removed with 
the cancer varies according on the cancer’s features, whether it has spread, and 
the patient’s particular emotions. The following are a handful of the most com-
mon types of surgery:
a. Lumpectomy (breast conserving surgery)
According to the American Cancer Society [33], a lumpectomy, also known as a 
selective mastectomy, is a practice that requires removing the portion of the breast 
that contains the malignant tumour, as well as some healthy tissues and lymph 
nodes around it, while leaving the rest of the breast preserved as much as possible. 
This operation is often performed on women in the early stages of cancer, but in 
addition to the surgery, the patient will need additional treatments such as radia-
tion, chemotherapy, or hormone replacement therapy. Most surgeons and pa-
tients, particularly if the woman is going to lose her breast, prefer a lumpectomy 
over a full breast removal at first. Tenderness, transient inflammation, sclerosis, 
and a change in the look of the breast are all possible side effects of a lumpectomy.
b. Mastectomy
The purpose of a mastectomy is to reduce the chance of developing breast can-
cer. Bilateral preventive mastectomy reduces the risk of getting breast cancer 
but does not fully remove it. Aromatase and tamoxifen are more effective than 
contra-lateral preventive mastectomy in reducing the risk of contra-lateral 
breast cancer. Mastectomy is the most efficient treatment for a disseminated 
instance of breast cancer in whom a lumpectomy was ineffective.
Nonetheless, most women experience feelings of asexuality, loss of self-image, 
and melancholy as a result of breast loss [34].
c. Reconstructive surgery
Females who have had a mastectomy might consider having their breasts  
renovated, either immediately or later. It is used to improve the appearance of 
the breast after tumour surgery. All ladies who have had a mastectomy should be 
given the choice of reconstructive surgery [35]. Mastectomy is a very straightfor-
ward surgical procedure that usually requires 1–2 days in the hospital. Breast mass 
deficiency alters the patient’s appearance and makes it difficult to wear certain 
types of clothes. The use of an external prosthesis to address these issues may be 
uncomfortable and abrasive, especially for women with large breasts. The most 
serious side effect after mastectomy is the psychological impact of the physical 
and cosmetic changes, which may include anxiety, sorrow, and poor effects on 
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body image and sexual activity [36]. Females with breast cancer who are unable to 
get breast-conserving therapy or who have a higher genetic risk of breast cancer 
often seek breast reconstruction. Breast reconstruction methods now available are 
varied and may include the use of a prosthetic implant, an autologous tissue flap, 
or both. Cancer may recur in the rebuilt breast regardless of the technique used; 
furthermore, in autologous tissue flaps repaired breasts, minor complexity such 
as fat necrosis may occur. Breast reconstruction, according to studies, restores 
body representation, demonstrates vitality, femaleness, and sexuality, and has a 
positive impact on the patient’s emotions of comfort and life quality [37].
4. Ovarian ablation as adjuvant therapy for breast cancer
Breast cancer patients have been treated with ovarian ablation. Radiation-
induced ovarian ablation, surgical removal of the ovaries, and long-term use 
of luteinizing hormone-releasing hormone (LHRH) analogues are all options 
for ovarian ablation. Furthermore, there are a few theories that cytotoxic 
chemotherapy may help premenopausal women with breast cancer by causing 
ovarian ablation. Many of the case studies and clinical trials of ovarian excision 
conducted in the past had methodological flaws. A meta-analysis of ran-
domised clinical trials found that women who had ovarian ablation as an adju-
vant therapy had a significant improvement in overall survival and disease-free 
survival compared to those who did not. According to a study of the literature, 
ovarian ablation may be used as an alternate treatment for breast cancer [38].
3. Breast cancer therapy by class
Various classes of therapeutic agents are employed for breast cancer treatment:
a. Alkylating agent: cyclophosphamide (nitrogen mustard)
b. Anti-metabolite: methotrexate (folic acid analogue), 5-fluorouracil 
&capacitabine (pyramidine analogues)
c. Natural product: vinorelbine (vinca alkaloid), paclitaxel (taxane),  
doxorubicin (antibiotic)
d. Hormone and antagonist: tamoxifen (anti oestrogen), letrozole&anastrazole 
(aromatase inhibitors)
e. Miscellaneous: trastuzumab (monoclonal antibody), lapatinib (Protein 
tyrosine kinase inhibitor)
4. Chemotherapy
Chemotherapy is the process of eliminating cancer cells with the help of specific 
medications. It may be administered both before and after surgery, depending on 
the patient’s health. Docetaxel, Paclitaxel, Platinum agents (cisplatin, carbopla-
tin), Vinorelbine (Navelbine), Capecitabine (Xeloda), Liposomal doxorubicin 
(Doxil), Cyclophosphamide (Cytoxan), Carboplatin (Paraplatin), and other drugs 
are included in chemotherapy, according to the American Cancer Society [39]. 
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However, it has a number of negative side effects. The following are some of the 
most frequent breast cancer treatment regimens.
Cyclophosphamide is used to treat breast cancer metastases by preventing DNA 
replication and cell division. This prodrug is converted into active metabolites by hepatic 
intracellular enzymes (i.e. 4 hydroxy cyclophosphamide, aldophosphamide, acrolein 
and phosphor amide mustard). The medication has been utilised in the treatment of 
breast cancer as an adjuvant therapy in conjunction with CMF or an anthracycline.
Platinum compounds such as Carboplatin and Cisplatin are used to treat breast 
cancer as monotherapy or in conjunction with other cancer treatments. Platinum 
compounds have been investigated for their effect on DNA structure and stabil-
ity, and a variety of platinum-DNA adducts have been discovered in vivo and in 
vitro. The impact of these different lesions on DNA replication, their potential to 
introduce mutations, and their susceptibility to DNA repair methods have all been 
measured in the early studies. Platinum (IV) compounds may cause further DNA 
damage, perhaps as a result of the cell’s conversion to platinum (II) compounds. 
About 20–35 percent of patients with metastatic breast cancer who were receiving 
monotherapy responded to carboplatin treatment. The medicines Gemcitabine and 
Taxanes are often used in conjunction with Platinum compounds.
Capecitabine is a fluoropyrimidine oral prodrug that, when converted to 5-FU by the 
thymidine phosphorylase enzyme, has comparable effects as 5-FU infusion. It has been 
used in conjunction with taxanes to treat metastatic breast cancer that has progressed.
Gemcitabine (also known as difluorodeoxycytidine) is a pyrimidine nucleotide 
that inhibits RNA synthesis and DNA replication and is used to treat malignancies of 
the lung, bladder, and breast. Weekly IV injections of gemcitabine are well tolerated.
Vinorelbine binds to tubulin, causing mitotic metaphase to be disrupted. 
According to several studies, this medication has shown encouraging effects in 
advanced breast cancer.
Although metastatic or secondary breast cancer is difficult to cure, it may be man-
aged for years. Chemotherapy may be used to control metastatic breast cancer and 
slow or stop its progression. It may also be used to reduce the severity of certain symp-
toms. Other treatments may be started before to or concurrently with chemotherapy.
5. Aromatase inhibitors
These are compounds that target aromatase, the enzyme complex that is respon-
sible for the last step in the synthesis of oestrogen, in order to reduce oestrogen 
formation. Letrozole, exemastane, and anastrozole are examples of third-genera-
tion aromatase inhibitors that are currently used. A randomised clinical study that 
looked at the efficacy of these chemicals in treating women with advanced breast 
cancer found that they are quite beneficial. Females treated with aromatase inhibi-
tors had a lower risk of developing contralateral breast cancer than women treated 
with tamoxifen, according to a clinical trial [40].
6. Anti–angiogenesis drugs
Antiangiogenic therapy for breast cancer has a lot of potential and several 
ongoing studies are attempting to better understand the optimal care settings and 
mediator selection. Research suggests a link between endocrine resistance and cancer 
dependency on angiogenic networks in patients with oestrogen receptor positive 
tumours, suggesting a possible therapeutic benefit in combining endocrine treatment 
with antiVEGF mediator. Results from randomised clinical trials highlight the wide 
range of responses to antiVEGF therapy, indicating that a better selection of patient 
subgroups is needed to maximise the benefits of these treatments. The identification 
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of biomarkers for treatment response is a single area of intense interest, however 
most studies to far have failed to find a correlation between cancer-associated indica-
tors such as cancer mutations and EGF expression and scientific response.
7. Radiation therapy
Radiation treatment is beneficial in early breast cancer patients, according to 
Zhou et al. This research looked at 143 women who had breast conserving surgery 
and received either regular or intraoperative radiation treatment. There was sub-
stantial local control of the tumour after 54 months of follow-up. Radiation treat-
ment uses high-energy beams to destroy cancer cells. Only the cells that are treated 
are affected by this treatment. After breast cancer surgery, radiation treatment may 
be used to eliminate any residual cells in the chest region [41].
a. Brachytherapy
It’s a type of radiation treatment. Accelerated partial breast irradiation is a term 
that comes to mind. It just focuses radiation in the general region where the cancer 
was discovered. This might potentially eliminate the need for whole-breast radio-
therapy. The number of management sessions is also reduced.
8. Protein tyrosine kinase inhibitor
Lapatinib is an orally active, reversible EGFR and HER2 tyrosine kinase inhibi-
tor whose primary mechanism of action tends to be driven by HER2. When trastu-
zumab-treated HER2-positive breast cancer developed, lapatinib was authorised 
for use in combination with capecitabine; it’s also utilised as a first-line treatment 
for HER2-positive metastatic breast cancer in combination with letrozole. Lapatinib 
and chemotherapy combined achieved a 22 percent response rate and a 27 percent 
clinical value rate in patients who had previously been treated with trastuzumab, 
and as prophylaxis, it achieved 12.4 percent to 25 percent clinical value rates; how-
ever, constrained resistance to lapatinib was observed in some cases [42, 43].
9. Gene therapy for carcinoma of the breast
Gene therapy is a kind of treatment that attempts to correct particular molecular 
defects related to breast cancer growth and progression. Cancer development is linked 
to mutated BRCA1 and p53 genes, which have been identified as cancer genetic markers. 
[44]. Cancer gene modification techniques may allow for selective targeting without 
presenting substantial hazards to non-cancer cells since cancer cells are the only ones 
that suffer mutational inactivation of gene activity in these circumstances. Even BRCA1 
and p53 have been found to limit tumour cells without mutations in these genes, sug-
gesting that so-called gene modification methods may be more effective than previously 
believed. These and other genes have been discovered as possible targets for gene substi-
tution therapy as cancer genetics has become more well-known. Early patient investiga-
tions using BRCA1 and p53 gene therapy have shown a lot of encouraging indications 
of effectiveness, but they have also highlighted areas where additional clinical trials are 
required before these treatments may be widely utilised in breast cancer patients.
10. Cancer stem-cell therapy for breast cancer
The cancer stem-cell idea is based on recent breast biology studies. According 
to two key aspects of this theory, cancer arises in progenitor cells or mammary 
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stem cells as a result of a dysregulation of the normally tightly controlled mecha-
nism of self-renewal. As a result, cancers contain a cellular component that retains 
basic stem-cell functions including self-renewal, differentiation, and tumori-
genesis while also being accountable for cellular heterogeneity. Advances in the 
stem-cell field have assisted the identification of stem cells in both normal and 
malignant breast tissue. The finding of these stem cells has assisted in identifying 
the origins of human breast cancer’s genetic complexity. In the early diagnosis, 
prevention, and treatment of human breast cancer, the cancer stem-cell hypothesis 
is critical. Dysregulation of stem cell renewal pathways is linked to both sporadic 
and hereditary breast cancers. These abnormal stem cells might be utilised to 
create novel cancer prevention methods. Moreover, because breast cancer stem 
cells may be resistant to chemotherapy and radiation, efficient targeting of this 
cell type may be required for the development of novel effective treatments for 
breast cancer.
11. Monoclonal antibodies
Trastuzumab is a physiologically active, humanised monoclonal antibody 
that acts against the extracellular domain IV of HER2 and has increased 
survival rates in HER2/neu positive breast cancer patients. This monoclonal 
antibody is clinically safe and effective when used in a three-week cycle, and it 
may also be used in conjunction with paclitaxel, gemcitabine, vinorelbine, or 
carboplatin.
12. Immunotherapy
To combat cancer cells, it makes use of the body’s immune system. One of the 
examples is a cancer vaccination. Vaccines are made using cancer cell parts or cancer 
cells themselves. These cells activate the immune system, which aids in the attack 
and destruction of cancer cells. Immunotherapy has become an important compo-
nent in the treatment of breast cancer. At the moment, HER2 targeted treatment is a 
significant element of HER2 over expressing breast tumour therapy.
Trastuzumab, in combination with the newer additions of pertuzumab and 
TDM1, provides significantly better breast cancer prediction.Immunotherapies 
are progressing in the field of development, with several FDA-approved antibody 
treatments being utilised in adjuvant and metastatic situations. Current gains in 
targeted treatments, robust specific immunotherapy, and grip ensure that general 
endurance in the adjuvant context will continue to improve. The very precise and 
focused vaccination treatment method not only avoids the side effects of contem-
porary standard of care medicines, such as active and passive immunotherapies 
like ipilimumab, but also provides a remedial strategy for those who are not 
HER2-overexpressing. Despite the fact that vaccinations for breast cancer have 
been mostly unsuccessful in previous clinical studies, the majority of these studies 
were done in the setting of advanced age metastatic disease, which is an unfavour-
able environment for medicines designed to halt, rather than manage disease.
Immunogenicity is now showing a connection with medical response in adjuvant 
situations, according to current clinical research.
8. Drugs used for breast cancer
FDA approved and clinical status of investigational drugs for breast cancer 























Anticancer agent Target & application Clinical status Type
5-fluorouracil Palliative treatment of breast cancer Approved Treatment
Abemaciclib HR+ and HER2− advanced/metastasized cancer Approved Treatment
Abemaciclib (LY2835219) Rb+ TNBC that is recurrent,locally advanced,metstatic or cannot be removed by surgery Phase II Treatment
Ado-Trastuzumab emtansine HER2+ metastasized and recurrent cancer has already been treated with trastuzumuab and a 
taxane
Approved Treatment
Alisertib with or without fulvestrant Locally advanced ot metastatic, endocrine – resistant breast cancer Phase II Treatment
Anastrozole Postmenopausal women early stage, HR+ metastatic breast cancer advanced breast cancer that 
has gotten worse after treatment with tamoxifen citrate
Approved Treatment
Anastrozole or letrozole HR+ stage II-III breast cancer that can be removed by surgery Phase I Treatment
Cabozantinib with or without fulvestrant HR+ metastatic stage cancer with bone involvement Pilot phase II Treatment
Capecitabine Metastasized cancer whose dieases has not gotten better with other chemotherapy *metastatic 
breast cancer
Approved *phase II Treatment
Cyclophosphamide Breast cancer *mesothelin-targeted T-cells after treating patients with metastatic, mesothelin 
expressing, HER2− breast cancer
Approved *phase I Treatment
Dendritic cell vaccine + gemcitabine hydrochloride Metastatic breast cancer Pilot early phase I Treatment
Docetaxel Locally advanced or metastasized breast cancer that is node –positive and can be removed by 
surgery
Approved Treatment
Docetaxel + carboplatin Neoadjuvant treatment of stage II-III TNBC Phase II Treatment
Doxorubicin hydrochloride Adjuvant therapy for braest cancer that has spread to the lymoh nodes after surgery Approved Treatment
Epirubicin hydrochloride After whose cancer has spread to the lymph nodes under the arm Approved Treatment
Eribulin mesylate Metastasized breast cancer who have already been treated with anthracycline and taxane 
*brain metastases from breast cancer
Approved *phase II Treatment
Eribulin mesylate or paclitaxel Recurrent stage IIIC-IV breast cancer Randomised phase 
III
Treatment







































Anticancer agent Target & application Clinical status Type
Everolimus Advanced HR+/HER2− and has not gotten better after treatment with letrozole or anastrozole Approved Treatment
Exemestane Early stage and ER+; postmenopausal women who have already been treated with tamoxifen 





Fulvestrant Postmenopausal women with HR+ and HER2− advanced cancer Approved Treatment
Gemcitabine hydrochloride Metastasized breast cancer that has gotten better with other chemotherapy Approved Treatment
Goserelin acetate Premenopausal and perimenopausal women with advanced breast cancer Approved Treatment
Ixabepilone Advanced metastasized who have not gotten better with other chemotherapy Approved Treatment
Lapatinib ditosylate HR+/HER2+ breast cancer Approved Treatment
Letrozole Early stage, HR+ / HER2+ advanced metastatic breast cancer Approved Treatment
Megestrol acetate Palliative treatment of advanced disease in breast cancer Approved Treatment
Methotrexate Breast cancer *breast cancer and leptomeningeal metastasis Approved *phase II Treatment
Neratinib Stage IV HER2+ breast cancer Phase II Treatment
Olaparib Metastatic breast cancer with certain mutations in the BRCA1 or BRCA2 genes whose have 
HER2−*triple negative non-metastatic breast cancer who have completed definitive local 





Paclitaxel Breast cancer Approved Treatment
Paclitaxel albumin-stabilised nanoparticle 
formulation (Abraxane)
Recurred (come back) or metastasized cancer Approved Treatment
Palbociclib (Ibrance) HR+ and HER2−advanced or metastasized cancer Approved Treatment
Pamidronate sodium
Raloxifene hydrochloride
• Invasive breast cancer in postmenopausal women who have osteoporosis
• Selective benzothiopene oestrogen receptor modulator (SERUM) with lipid lowering 

























Anticancer agent Target & application Clinical status Type






Tamoxifen citrate Metastasized (spread to other parts of the body) breast cancer Approved Treatment
Thiotepa Breast cancer Approved Treatment
Toremifene Metastasized breast cancer and postmenopausal with ER+ or ER− Approved Treatment
Trastuzumab Breast cancer that is HER2+ Approved Treatment
Trastuzumab emtansine HER2 amplified or mutant advanced cancer Phase II Treatment
Vinblastine sulfate Breast cancer that has not gotten better with other treatment Approved Treatment
Combination therapy
AC
A = doxorubicin hydrochloride(Adriamycin)
C = cyclophosphamide
Primary, recurrent and metastatic breast cancer Approved Treatment
AC-T
A = Doxorubicin hydrochloride (Adriamycin) 
C = cyclophosphamide
T = paclitaxel
Adjuvant treatment of breast cancer Approved Treatment
CAF
C = cyclophosphamideA = Doxorubicin 
hydrochloride (adriamycin)
F = fluorouracil
















































Anticancer agent Target & application Clinical status Type
FEC
F = fluorouracil
E = epirubicin hydrochloride
C = cyclophosphamide
Adjuvant setting and also for the treatment of recurrent and metastatic breast cancer Approved Treatment
TAC
T = docetaxel (Taxotere)
A = Doxorubicin hydrochloride (adriamycin)
C = cyclophosphamide
Adjuvant treatment for breast cancer Approved Treatment
Table 1. 
List of FDA approved and clinical status of investigational drugs for breast cancer treatment (source: NH-NCI, U.S).
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9. Endocrine resistance for breast cancer
ER is expressed in around 70% of breast malignancies and plays an important 
role in their genesis and progression. Because of the involvement of ER in ER+ 
breast cancer, endocrine treatments such as aromatase inhibitors (AIs), selective 
oestrogen receptor modulators (SERMs), and selective oestrogen receptor degrad-
ers are commonly used to treat these tumours (SERDs). While hormone treatments 
have been successful in avoiding recurrence, about 20% of these tumours acquire 
resistance to hormone therapies and will return.
10. Drugs that block oestrogen receptors
These medicines operate by preventing oestrogen from driving the growth of 
breast cancer cells.
1. Selective oestrogen receptor modulators (SERMs)
The “selective” in the acronym SERMs alludes to the unique regulation of the 
oestrogen receptor and the downstream effect on ER signalling that happens inside 
various organs. Tamoxifen, for example, is known to have anti-proliferative (or 
antagonistic) effects in breast tissue while having agonistic or partial agonistic 
effects on the uterus, bone, and heart. In both the usage of SERMs and the creation 
of new medicines, the ratio of therapeutic benefit to negative tissue-specific effects 
has been an essential factor to address [46].
a. Tamoxifen
Tamoxifen has been effectively used to treat breast cancer in both premeno-
pausal and postmenopausal women at all stages. It’s utilised as a palliative treatment 
for those who have advanced cancer, as well as an adjuvant treatment after surgery 
for node-negative or positive cancer. Tamoxifen has consistently prolonged disease-
free intervals as a postsurgical adjuvant therapy for early breast cancer with a low 
frequency of side effects. It is possible to achieve a 20% decrease in 5-year mortality, 
with the reduction being most noticeable in women over 50. Tamoxifen is used to 
reduce the risk of breast cancer and invasive breast cancer in women who are at high 
risk for the disease, as well as those who have ductal carcinoma in situ. Negative 
oestrogen receptor tumours do not respond to treatment [47].
b. Role of tamoxifen:
For individuals with oestrogen receptor (ER)-positive breast cancer, anti-
oestrogen tamoxifen has been the endocrine therapy of choice. Tamoxifen decreases 
the risk of recurrence following surgery when used as an adjuvant treatment. 
Tamoxifen provides an objective clinical response in half of the individuals with 
recurrent illness. The cancer, on the other hand, will eventually become hormone-
independent, meaning it will no longer respond to tamoxifen. Despite significant 
research, resistance mechanisms remain mostly understood [48].
Tamoxifen’s hopeful profile spurred a slew of clinical studies and decades of 
anti-oestrogen research, which revealed new details about ER biology and its link to 
ER-dependent malignancies. There have been several randomised studies of adju-
vant tamoxifen in early breast cancer patients. Before recurrence, information on 
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every woman in any randomised study of adjuvant tamoxifen versus no tamoxifen 
that began before 1990 was sought in 1995. The overall effects of tamoxifen proved 
to be minor among these women, therefore following studies of recurrence and 
total mortality are limited to the remaining women [49].
The effects of 1–2 years of tamoxifen and around 5 years of tamoxifen in 
the studies comparing tamoxifen vs. no adjuvant tamoxifen are summarised in 
Tamoxifen versus No Tamoxifen. The studies are separated by ER status, which is 
categorised as ER-poor, ERpositive, and ER-unknown, according to the recognised 
importance of the original tumour’s hormone receptor status. Current and future 
assessments of receptor state may be more predictive of response as procedures 
for assessing receptor status advance. ER measures were, on average, extremely 
significant predictors of response to 5 years of adjuvant tamoxifen, despite the fact 
that it may be difficult to characterise the receptor assays employed in these stud-
ies many years ago. Many of the effects and side effects of tamoxifen in ER breast 
cancer patients are random [50].
2. Selective oestrogen receptor degraders (SERDs)
A selective oestrogen receptor degrader or downregulator (SERD) is a medica-
tion that binds to the oestrogen receptor (ER) and causes the ER to be degraded and 
therefore downregulated in the process. They’re utilised with earlier types of medi-
cines including selective oestrogen receptor modulators (SERMs) and aromatase 
inhibitors to treat oestrogen receptor-sensitive or progesterone receptor-sensitive 
breast cancer.
Selective oestrogen receptor degraders (SERDs) are oestrogen receptor antago-
nists that also cause proteasome-mediated ER degradation. Fulvestrant is a therapy 
for ER+ advanced breast cancer that has been authorised by the FDA [51].
a. Fulvestrant
Fulvestrant is an oestrogen receptor antagonist that inhibits and destroys oestro-
gen receptors. This medication is not a SERM; rather, it works as an anti-oestrogen 
throughout the body. It’s referred to be an oestrogen receptor degrader that’s selec-
tive (SERD). Fulvestrant is at least as effective and safe as comparator endocrine 
treatments in postmenopausal women with advanced hormone-sensitive breast 
cancer. Fulvestrant is a safe and effective systemic medication that can be regarded 
as a viable therapeutic option for postmenopausal women with hormone-sensitive 
advanced breast cancer in the treatment sequence [52].
Fulvestrant is a steroidal ER antagonist that was developed for its lack of 
agonism in almost all types of tissues studied, but it was subsequently shown to 
be a SERD that causes ER to be ubiquitinated and destroyed by the proteasome. 
It is, in fact, the only FDA-approved treatment for postmenopausal women who 
have relapsed on hormone therapy and have advanced ER-positive breast cancer. 
Fulvestrant, on the other hand, has an unfavourable pharmacokinetic profile and 
requires a painful intramuscular injection to be administered (500 mg dose). 
Stable-state plasma concentrations require 3–6 months to achieve, even with 
improved loading-dosage regimens (500 mg dose on days 1, 15, and 29). Its overall 
therapeutic efficacy is limited by the poor ER turnover seen in patient cases (less 
than 50%), compared to complete receptor downregulation shown in in-vivo 
breast cell line investigations. As a result, there is still an unmet medical need 
for a potent orally available SERD capable of reaching higher levels of malignant 
exposure [53].
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b. Mechanism associated with ER Suppression:
Resistance to oestrogen suppression or inactivation of ER by other methods 
(SERMs/SERDs) is linked to and/or caused by mechanisms. Although the phrase 
“endocrine resistance” technically refers to resistance to oestrogen suppression, we 
use it here to refer to oestrogen or ER suppression resistance.
In ER+ metastatic breast cancer, endocrine resistance is an unavoidable out-
come (MBC), As a result, when CDK4/6 inhibitors (e.g., palbociclib, ribociclib, 
abemaciclib) are added to antiestrogens, progression-free survival in patients 
with ER+ MBC is significantly increased compared to antiestrogens alone. The 
addition of CDK4/6 inhibitors to antiestrogens abrogates some of the resistance 
mechanisms. However, in early-stage cancers, they might still be important 
drivers of hormone resistance. The Figure 5 was indicating that the activa-
tion of HER2, EGFR, FGFR, and Other RTKs Promotes Endocrine Resistance, 
RTK activation is augmented by PI3K and MAPK signalling, which induces ER 
phosphorylation and promotes ligand-independent ER activation (most often 
by mutation or amplification). NF1 loss-of-function mutations activate Ras 
in a constitutive manner, which can activate the PI3K and MAPK pathways as 
well. In a ligand-independent way, ER phosphorylation increases transcription 
of ER-regulated genes. ER and oncogenic RTK signalling both target CCND1, 
the gene that encodes cyclin D1. RTKs activate additional transcription factors 
Figure 5. 
Activation of HER2, EGFR, FGFR, and other RTKs.
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that promote ER-independent survival in addition to ER. The combination of 
an ER antagonist with the appropriate RTK inhibitor CDK4/6 inhibitor might 
potentially overcome RTK-mediated endocrine resistance. Sensitivity to endo-
crine treatment and resistance to it in ER+ breast cancers are similar to other 
hormone-dependent malignancies including prostate cancer and endometrial 
cancer [54, 55].
11. Concept of selective oestrogen receptor modulation
SERMs are estrogenic and antiestrogenic molecules that have a wide range of 
effects. Two SERMs are now accessible in clinical trials: tamoxifen for breast cancer 
prevention and raloxifene for osteoporosis prevention. Tamoxifen was first created 
as an antiestrogen to treat breast cancer. Tamoxifen’s widespread use as a therapy 
for all stages of ER-positive breast cancer in men and women has been assisted by 
its low risk of adverse effects. Concerns about the effects of an antiestrogen on bone 
density and the risk of CHD were raised when the strategy of testing long-term 
(5 years) tamoxifen therapy in ER-positive, lymph node-negative women and the 
proposed testing of tamoxifen as a preventive agent in high-risk women were pro-
posed in the mid-1980s. Tamoxifen, on the other hand, is not a pure antiestrogen; 
it has antiestrogenic as well as estrogenic properties [56]. According to laboratory 
studies, tamoxifen is a selective oestrogen in areas like bone but an antiestrogen 
in breast tissue, preventing carcinogenesis and tumour development. Laboratory 
investigations dating back to the 1980s [57, 58] have confirmed raloxifene’s SERM 
activity.
11.1 Mechanisms of action
Even though exact molecular mechanism of oestrogen or SERMs at the ER 
is unknown, two ERs govern oestrogen activity in target tissues: 1) ER, the 
traditional ER [59]; and 2) ER, which controls the action of ER and decreases 
tamoxifen’s oestrogen-like effects [60, 61]. Although the crystal structure of the 
whole ER has yet to be determined by x-ray crystallography, data on the ligand-
binding domains conjugated with estrogens and SERMs has been published. 
The outer forms of oestrogen and SERM complexes have been better under-
stood as a result of this information. Oestrogen receptors (ERs) are nuclear 
transcription factors that bind estrogens, dimerize, and form a transcription 
complex with coactivators and other molecules to help unwind DNA. At oestro-
gen-responsive genes, RNA polymerase produces messenger RNA. SERM–ER 
complexes appear to alter the signal transduction route to oestrogen-responsive 
genes (through oestrogen response elements [EREs]) by binding a corepressor 
protein or activating fewer or different coactivators. This is, however, a simplis-
tic model of oestrogen and antiestrogen action that overlooks the nuances of 
SERM function.
12. Drugs repurposed for breast cancer treatment
The commercially approved drugs that were originally used for diseases other 
than breast cancer are discussed in the following section. These medicines, on the 
other hand, are now being used or researched for breast cancer treatment. The drug 
candidates repurposed for breast cancer are divided into categories based on how 
they work (Table 2).
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13. Executive summary
Breast cancer is still a significant public health problem, even though it was 
first reported more than 3500 years ago. This is particularly true in light of most 
societies’ substantial and harmful lifestyle changes. At both the epidemiological 
and molecular levels, breast cancer is diverse. Many significant breast cancer risk 
factors have been discovered by clinical and epidemiological data, including age, 
family history, early menarche, and medical history; variables that are intangible 
or beyond our control. However, about 70% of breast cancers nowadays are caused 
by risk factors that may be altered or avoided. Obesity, lack of exercise, smoking, 
drinking, and nutrition, as well as other variables that may have a detrimental 
impact on a woman’s hormonal environment, are among them. These important 
rate-limiting measures in the battle against breast cancer should not be ignored. As 
discussed in this review, significant advances in cancer biology have led to signifi-
cant advancements in cancer early detection, therapy, and prevention in recent 
years. The growing emphasis on personalised treatment, as well as the combination 
of targeted and immunological therapies with current therapeutic techniques, 
holds potential for the cure of breast cancer. Drug resistance in breast cancer is a 
complicated clinical condition caused by a variety of molecular changes. Because 
chemotherapy is often used in conjunction with targeted treatments for the ER+ or 
HER2+ subtypes in clinical practice, targeted therapy-induced resistance may lead 
to chemo-resistance and vice versa. Treatment methods and therapeutics must be 
specially developed to address each distinct resistance mechanism in various clinical 
circumstances in response to every particular resistance mechanism. Early clini-
cal trials are looking for drugs that target each route individually. Clinical studies 
Drug Chemical name Mechanism Original indication
Alkylating agent Cyclophosphamide Inhibits DNA 
replication by 
damaging genetic 
material of the cell
As immuno-modulator in 
autoimmune diseases
Thiotepa Immunosuppressant
Anthracyclins Doxorubicin DNA intercalation Antibiotic from Streptomyces 
peucetius bacterium
Capecitabine Colon cancer




keratosis, and skin warts
Gemcitabine Anti-viral drug
Methotrexate Leukaemia
CDK 4/6 inhibitor Palbociclib, Palbonix Interferes with cell 
cycle
CDK 4/6 inhibitor
Tamoxifen Albright syndrome, 
ovulation induction
HT-SERM Toremifene Binds to ER Infertility with an ovulatory 
disorders




Letrozole Lowers oestrogen 
amount
Induction of ovulation
Anastrazole Induction of ovulation
Table 2. 
A list of repositioned drugs approved for breast cancer treatment.
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investigating tailored medication delivery methods are also underway in the mean-
while. These therapeutic agents may enter cells through receptor-mediated endo-
cytosis, thereby bypassing typical drug resistance mechanisms such as drug efflux 
pumps, cell surface docking site mutations, and so on, allowing them to overcome 
drug resistance. The heterogeneity of breast cancer cells, on the other hand, poses 
major difficulties in terms of treatment response and may be a contributing factor 
in drug resistance. Tamoxifen, a selective oestrogen receptor modulator, is claimed 
to be used as a therapy for all stages of oestrogen receptor (ER)-positive breast can-
cer in men and women, thanks to its low risk of adverse effects. Notwithstanding 
major investments in prevention and treatment, breast cancer remains the primary 
cause of cancer mortality in women throughout the world. The existing therapeutic 
options are both expensive and have serious negative effects.
Drug repurposing, or finding new applications for existing therapies, has arisen 
as an unique drug development strategy. Repositioning existing, off-patent non-
cancer medicines with established targets into newer indications is like repurposing 
outdated weaponry for a new war. The process of medication repurposing has been 
made easier thanks to developments in genomics, proteomics, and information 
computational biology. The repositioning method not only speeds up the medica-
tion development process, but it also results in more effective, less expensive, 
and safer medicines with fewer/known adverse effects. Alkylating compounds, 
anthracyclins, antimetabolites, CDK4/6 inhibitors, aromatase inhibitors, mTOR 
inhibitors, and mitotic inhibitors have all been repurposed for breast cancer therapy 
in the recent decade.
14. Conclusion and future perspectives
Medical experts are enthusiastic about the increasing management methods, 
but they are concerned that resources will be inadequate to get these therapeutics to 
advanced clinical trials. The difficulties are therefore to choose the most competent 
drugs to be examined, as well as the appropriate clinical trials to conduct such 
assessments. Over the last several years, new drugs targeting particular therapeutic 
targets have resulted in significant advances in the treatment of breast cancer. 
Resistance to systemic therapy (endocrine and others), expensive treatment, and 
limited availability of adequate cancer care in many countries remain challenges. 
We must continue to improve our available technology in order to provide proper 
guidance for those living with the disease, as well as those at high risk of developing 
it, and to develop new, more effective therapies in order to significantly improve 
the outcomes of breast cancer patients around the world. Individualising therapies 
offers the potential of helping patients through challenging treatment choices in 
order to enhance their long-term results. In this review, we have uncovered the most 
well-documented therapy options and potential technologies in the fight against 
breast cancer. We go through the benefits of medication repurposing for breast 
cancer treatment in depth in this article. We offered a number of medicines that 
were effectively repurposed for the treatment of breast cancer. Preclinical investiga-
tions have shown that a combination of chemotherapies and a medication repurpos-
ing strategy might produce promising results. The possibility of non-cancer drugs 
being studied for breast cancer in the future, as well as the obstacles and bottlenecks 
of drug repurposing, were also highlighted. As a result, we draw the conclusion that 
combining system biology and bioinformatics to select the most appropriate gene-
protein-pathway-target-drug modelling has a high potential for providing more 
efficient, safer, and cost-effective chemotherapeutics for the treatment of even the 
most severe forms of breast cancer.
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